Show simple item record

dc.contributor.authorAcerini, Carloen
dc.contributor.authorSegal, Daviden
dc.contributor.authorCriseno, Sherwinen
dc.contributor.authorTakasawa, Keien
dc.contributor.authorNedjatian, Naviden
dc.contributor.authorRöhrich, Sebastianen
dc.contributor.authorMaghnie, Mohamaden
dc.date.accessioned2018-12-12T00:31:33Z
dc.date.available2018-12-12T00:31:33Z
dc.date.issued2018-01en
dc.identifier.issn1664-2392
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286720
dc.description.abstractSeveral studies have shown that adherence to growth hormone therapy (GHT) is not optimal. There are several reasons why patients may not fully adhere to their treatment regimen and this may have implications on treatment success, patient outcomes and healthcare spending and resourcing. A change in healthcare practices, from a physician paternalistic to a more patient autonomous approach to healthcare, has encouraged a greater onus on a shared decision-making (SDM) process whereby patients are actively encouraged to participate in their own healthcare decisions. There is growing evidence to suggest that SDM may facilitate patient adherence to GHT. Improved adherence to therapy in this way may consequently positively impact treatment outcomes for patients. Whilst SDM is widely regarded as a healthcare imperative, there is little guidance on how it should be best implemented. Despite this, there are many opportunities for the implementation of SDM during the treatment journey of a patient with a GH-related disorder. Barriers to the successful practice of SDM within the clinic may include poor patient education surrounding their condition and treatment options, limited healthcare professional time, lack of support from clinics to use SDM and healthcare resourcing restrictions. Here we discuss the opportunities for the implementation of SDM and the barriers that challenge its effective use within the clinic. We also review some of the potential solutions to overcome these challenges that may prove key to effective patient participation in treatment decisions. Encouraging a sense of empowerment for patients will ultimately enhance treatment adherence and improve clinical outcomes in GHT.
dc.description.sponsorshipSupported from funds from industry (Novo Nordisk Ltd)
dc.format.mediumElectronic-eCollectionen
dc.languageengen
dc.publisherFrontiers Media
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleShared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.en
dc.typeArticle
prism.publicationDate2018en
prism.publicationNameFrontiers in endocrinologyen
prism.startingPage688
prism.volume9en
dc.identifier.doi10.17863/CAM.34027
dcterms.dateAccepted2018-11-02en
rioxxterms.versionofrecord10.3389/fendo.2018.00688en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-01en
dc.contributor.orcidAcerini, Carlo [0000-0003-2121-5871]
dc.contributor.orcidTakasawa, Kei [0000-0001-6947-4034]
dc.identifier.eissn1664-2392
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International